1Q Earnings Preview: What To Expect From US, EU Big Hitters
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
You may also be interested in...
Amgen Inc.'s first quarter revenue and earnings beat consensus estimates without a meaningful contribution from sales of the cholesterol-reducing biologic Repatha (evolocumab), but the company is pushing back against payers that are denying reimbursement to appropriate patients.
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.
Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.